MEDERA Trademark
MEDERA is a USPTO trademark filed by Medera Inc.. Status: Pending.
Trademark Facts
| Mark | MEDERA |
|---|---|
| Serial Number | 99036193 |
| Status | Pending |
| Filing Date | 2025-02-11 |
| Mark Type | Word |
| Nice Classes | 042 (Software & IT), 044 (Medical Services) |
| Owner | Medera Inc. |
| Attorney of Record | Anna Kurian Shaw |
| Prosecution Events | 23 |
| Latest Event | CNEA on 2026-04-29 |
Goods & Services
Class 042: Bacteriological research for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Biological research for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Biomedical research services for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Chemical research for others for use in gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Scientific research in the nature of conducting clinical trials for others; Conducting early evaluations for others in the field of new pharmaceuticals for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Development of biopharmaceutical preparations and medicines for gene and cell therapies for others for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Drug discovery services for others; Engineering services for others, particularly technical project planning and design engineering of lines for the processing of web products; Industrial research for others in the field of regenerative and reparative gene and cell therapies; Medical research laboratory services for others; Pharmaceutical research services for others; Pharmaceutical drug development services for others for gene and cell therapies for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Pharmaceutical product evaluation for others; Providing medical and scientific research information for others in the field of pharmaceuticals and clinical trials; Research and development of new products for others; Research and development of vaccines and medicines for gene and cell therapies for others for the treatment of cardiovascular diseases and systemic diseases associated with cardiac pathology; Scientific research for others in the field of gene therapy; Stem cell research services for others; Technical research for others in the field of pharmaceutical studies; Technology research for others in the field of regenerative gene and cell therapies; Class 044: Blood bank services; Human tissue bank services; Organ and tissue bank services; Stem cell therapy services; Medical services; Consultancy in the field of the medical treatment and diagnosis of cardiovascular diseases
Recent Prosecution Activity
| Date | Document | Type |
|---|---|---|
| 2026-04-21 | Response to Office Action | ROA |
| 2026-01-21 | Non-Final Action | NFIN |
| 2026-01-16 | Amendment and Mail Process Complete | AMC |
| 2026-01-16 | Response to Office Action | ROA |
| 2025-10-13 | Application Extension to Response | ELR |
| 2025-07-18 | XSearch Search Summary | XSS |
USPTO Refusals on Record
- unacceptable_specimen